...
首页> 外文期刊>Australian and New Zealand Journal of Obstetrics and Gynecology >Induction of labour: A comparison between controlled-release dinoprostone vaginal pessary (Cervidil(R)) and dinoprostone intravaginal gel (Prostin E2(R)).
【24h】

Induction of labour: A comparison between controlled-release dinoprostone vaginal pessary (Cervidil(R)) and dinoprostone intravaginal gel (Prostin E2(R)).

机译:引产:控释地诺前列素阴道子宫托(Cervidil(R))和地诺前列酮阴道内凝胶(ProstinE2®)之间的比较。

获取原文
获取原文并翻译 | 示例

摘要

Background: There are various prostaglandin preparations available for inducing labour. Controlled-release dinoprostone vaginal pessary is used in a number of centres in Australia and New Zealand. Aims: To compare the efficacy and safety of controlled-release dinoprostone vaginal pessary (Cervidil(R)) with dinoprostone intravaginal gel (Prostin E2(R)) for induction of labour. Methods: Retrospective cohort study of 969 women who were induced using either 10-mg controlled-released dinoprostone vaginal pessary (n = 507) or intravaginal dinoprostone gel (n = 462) at National Women's Health, Auckland City Hospital. Study outcomes included induction to delivery interval, mode of delivery, rate of oxytocin augmentation and incidence of uterine hyperstimulation. Results: Induction to vaginal birth interval was longer among nullipara receiving the pessary compared to those receiving intravaginal gel (21.5 vs 17.8 h, P = 0.004). There was no difference in rates of oxytocin augmentation or in mode of birth between pessary and gel groups. There was a trend to more uterine hyperstimulation among women induced with the pessary compared with those induced with intravaginal gel (22 (4.5%) vs 11 (2.4%) relative risk (RR) 1.9 (0.9-3.9)). Hyperstimulation associated with an abnormal fetal heart pattern (14 (2.9%) vs 2 (0.4%), RR 6.5 (1.5-28.9)) or treated with tocolytics (9 (1.8%) vs 1 (0.2%), RR 8.4 (1.1-66)) was more common in women who received the pessary. Conclusion: Use of dinoprostone vaginal pessaries did not shorten time to delivery or improve any other birth outcome measured compared to dinoprostone intravaginal gel. Clinically significant hyperstimulation appeared more common following use of the pessary. Large randomised controlled trials are needed to confirm or refute these findings.
机译:背景:有多种前列腺素制剂可用于引产。控释地诺前列素阴道子宫托在澳大利亚和新西兰的许多中心使用。目的:比较控释地诺前列素阴道阴道子宫托(Cervidil(R))和地诺前列酮阴道内凝胶(Prostin E2(R))诱导引产的功效和安全性。方法:回顾性队列研究在奥克兰市立医院的National Women's Health中使用10 mg控释的dinoprostone阴道子宫环(n = 507)或阴道内dinoprostone凝胶(n = 462)诱导的969名妇女。研究结果包括诱导分娩间隔,分娩方式,催产素增加的速率和子宫过度刺激的发生率。结果:与接受阴道凝胶剂相比,接受子宫托的未产妇对阴道分娩间隔的诱导时间更长(21.5 vs 17.8 h,P = 0.004)。子宫托和凝胶组之间催产素增加的速度或分娩方式没有差异。与阴道内凝胶诱发的子宫相比,与子宫内凝胶诱发的子宫相比,与子宫内凝胶诱发的子宫相比,子宫过度刺激的趋势有所增加(22(4.5%)vs 11(2.4%)相对风险(RR)1.9(0.9-3.9))。与胎儿心律异常相关的过度刺激(14(2.9%)vs 2(0.4%),RR 6.5(1.5-28.9))或接受了宫缩抑制剂治疗(9(1.8%)vs 1(0.2%),RR 8.4(1.1 -66))在接受子宫托的女性中更为常见。结论:与狄诺前列酮阴道内凝胶相比,使用狄诺前列酮阴道阴道环不会缩短分娩时间或改善任何其他分娩结局。使用子宫托后,临床上明显的过度刺激似乎更为常见。需要大型随机对照试验来确认或反驳这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号